Trial Profile
A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma - The GENESIS Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Motixafortide (Primary) ; Filgrastim
- Indications Stem cell mobilisation
- Focus Registrational; Therapeutic Use
- Acronyms GENESIS
- Sponsors BioLineRx
- 26 Mar 2024 According to a BioLineRx media release, poster of this trial was presented at the 2024 Tandem Meetings on February 21-24, 2024.
- 16 Feb 2024 According to a BioLineRx media release, new post-hoc subgroup analyses and pharmacodynamic and pharmacokinetic data will be presented at the 2024 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), taking place February 21-24, 2024, in San Antonio, Texas.
- 06 Feb 2024 Planned End Date changed from 22 Dec 2025 to 30 Sep 2029.